NCT01218997View on ClinicalTrials.gov

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

PHASE3CompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Alcoholism
Interventions
DRUG

Medisorb naltrexone 380 mg

Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.

DRUG

Oral naltrexone 50 mg

Tablet taken orally once daily for up to 1 year

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT01218997 - ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) | Biotech Hunter | Biotech Hunter